Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ADAP

ADAP - Adaptimmune Therapeutics Plc Stock Price, Fair Value and News

$0.010.00 (0.00%)
Market Closed

48/100

ADAP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

48/100

ADAP

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ADAP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADAP Price Action

Last 7 days

-50%

Last 30 days

-66.7%

Last 90 days

-80%

Trailing 12 Months

-98.0%

ADAP RSI Chart

ADAP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADAP Valuation

Market Cap

15.9M

Price/Earnings (Trailing)

-0.09

Price/Sales (Trailing)

0.24

EV/EBITDA

-0.1

Price/Free Cashflow

-0.08

ADAP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ADAP Fundamentals

ADAP Revenue

Revenue (TTM)

65.1M

Rev. Growth (Yr)

-89.33%

Rev. Growth (Qtr)

87.74%

ADAP Earnings

Earnings (TTM)

-169.8M

Earnings Growth (Yr)

-143.64%

Earnings Growth (Qtr)

36.24%

ADAP Profitability

EBT Margin

-255.12%

Return on Equity

-1.4K%

Return on Assets

-129.95%

Free Cashflow Yield

-1.2K%

ADAP Investor Care

Shares Dilution (1Y)

3.64%

Diluted EPS (TTM)

-0.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025179.6M65.1M00
202489.7M119.2M148.6M178.0M
202371.2M70.8M71.1M60.3M
20229.3M11.7M17.5M27.1M
20213.6M6.2M6.2M6.1M
20201.7M2.2M3.2M4.0M
2019040.0M20.6M1.1M
201843.2M48.7M62.3M59.5M
201714.1M17.3M42.1M37.8M
201614.7M12.2M9.7M14.2M
20155.3M9.9M12.2M14.5M
20140825.0K00
Get all data in R, Python etc through our Historical Stock Data APIs

About Adaptimmune Therapeutics Plc

ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
 CEO
 WEBSITEadaptimmune.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES534

Adaptimmune Therapeutics Plc Frequently Asked Questions

ADAP is the stock ticker symbol of Adaptimmune Therapeutics Plc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Mar 09 2026, market cap of Adaptimmune Therapeutics Plc is 15.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Mar 09 2026, ADAP's PE ratio (Price to Earnings) is -0.09 and Price to Sales (PS) ratio is 0.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADAP PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Adaptimmune Therapeutics Plc has provided -0.493 (multiply by 100 for percentage) rate of return.